Lancet

Article	Citations
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis	6498
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK	3778
RETRACTED: 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study	3313
Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic	2676
Alzheimer's disease	2084
Parkinson's disease	1622
Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants	1570
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 tr	1510
Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational	1383
Non-alcoholic fatty liver disease	1381
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia	1337
Global estimates of the need for rehabilitation based on the Global Burden of Disease study 2019: a systematic analysis for the Global Burden of Disease Study 2019	1311
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial	1300
Lung cancer	1192
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial	1168
Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic	1083
Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21	1064
The 2020 report of The Lancet Countdown on health and climate change: responding to converging crises	1058
Psoriasis	1048
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-	1048
Chronic pain: an update on burden, best practices, and new advances	987
Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study	972
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study	961
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials	940
Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment	898

Hepatocellular carcinoma	888
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label	876
Breast cancer	875
SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness	869
Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression	861
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial	823
Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021	805
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study	801
Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study	790
The 2021 report of the Lancet Countdown on health and climate change: code red for a healthy future	769
Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burd	758
1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study	758
Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study	723
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial	716
Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis	708
Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence	707
Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey	699
Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial	695
Liver cirrhosis	685
Hot weather and heat extremes: health risks	674
The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030	668
Ten scientific reasons in support of airborne transmission of SARS-CoV-2	655
Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019	655
Miscarriage matters: the epidemiological, physical, psychological, and economic costs of early pregnancy loss	653
Chronic kidney disease	644
Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the Z	641
Advanced reperfusion strategies for patients with out-of-hospital cardiac arrest and refractory ventricular fibrillation (ARREST): a phase 2, single centre, open-label, randomised controlled trial	628
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial	623
Immune checkpoint inhibitors in melanoma	614
COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study	592
Male infertility	591
The 2022 report of the Lancet Countdown on health and climate change: health at the mercy of fossil fuels	583
Gout	582
Lessons learnt from easing COVID-19 restrictions: an analysis of countries and regions in Asia Pacific and Europe	564
Nociplastic pain: towards an understanding of prevalent pain conditions	555
SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)	549
Acute respiratory distress syndrome	547
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled,	546
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial	544
Low back pain	541
Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study	537
Biliary tract cancer	527
Oxford–AstraZeneca COVID-19 vaccine efficacy	524
Endometriosis is a chronic systemic disease: clinical challenges and novel innovations	521
Bipolar disorders	512
Iron deficiency	509
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial	507
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial	506
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial	497
Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis	496

SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates	493
Endometrial cancer	493
Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination	478
Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study	469
Global, regional, and national prevalence estimates of physical or sexual, or both, intimate partner violence against women in 2018	469
Pre-eclampsia	466
Hearing loss prevalence and years lived with disability, 1990–2019: findings from the Global Burden of Disease Study 2019	454
Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial	454
Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study	447
Multiple myeloma	445
Osteoarthritis in 2020 and beyond: a Lancet Commission	444
Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study	443
SARS-CoV-2 variants and ending the COVID-19 pandemic	442
Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination	434
SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials	430
Time for united action on depression: a Lancet–World Psychiatric Association Commission	429
Irritable bowel syndrome	424
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial	418
Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2	407
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study	406
The Lancet Commission on lessons for the future from the COVID-19 pandemic	401
Schizophrenia	389
Head and neck cancer	389
The Lancet Commission on diabetes: using data to transform diabetes care and patient lives	388
Migraine: epidemiology and systems of care	388
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials	387
The Lancet Commission on the future of care and clinical research in autism	383
Cystic fibrosis	380
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cel	380
Chronic obstructive pulmonary disease	379
Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial	378
The global burden of cancer attributable to risk factors, 2010–19: a systematic analysis for the Global Burden of Disease Study 2019	373
Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial	368
Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals	364
The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study	362
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial	359
Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenS	352
Revisiting maternal and child undernutrition in low-income and middle-income countries: variable progress towards an unfinished agenda	349
Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial	349
Spike-antibody waning after second dose of BNT162b2 or ChAdOx1	347
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised	345
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 stu	345
Amyotrophic lateral sclerosis	341
Venous thromboembolism	341
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-grou	337
Type 2 diabetes	334
Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial	326
Guillain-Barré syndrome	325
IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial	323
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial	319
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controll	319
The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality	316
Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial	314
WHO International Standard for anti-SARS-CoV-2 immunoglobulin	313
Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study	311
Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial	311
Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial	310
Prostate cancer	308
Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum	303
Physical activity behaviours in adolescence: current evidence and opportunities for intervention	299
Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis	299
Body-mass index and obesity in urban and rural China: findings from consecutive nationally representative surveys during 2004–18	298
Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study	296
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study	295
Extracorporeal membrane oxygenation for COVID-19: evolving outcomes from the international Extracorporeal Life Support Organization Registry	294
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial	293
The first and second waves of the COVID-19 pandemic in Africa: a cross-sectional study	293
Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial	290
Fragmented health systems in COVID-19: rectifying the misalignment between global health security and universal health coverage	286
Anxiety disorders	284
Drug therapy for osteoporosis in older adults	282
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-infer	281
Association of metabolic–bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174 772 part	278
Functional gastrointestinal disorders: advances in understanding and management	278
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications	275
Functional dyspepsia	275
Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose	274
Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation	273
Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine	272
Reducing the health effects of hot weather and heat extremes: from personal cooling strategies to green cities	268

Considerations in boosting COVID-19 vaccine immune responses	266
Diagnostics for COVID-19: moving from pandemic response to control	265
Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission	263
Ulcerative colitis	262
Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial	259
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, pla	259
Report of the Lancet Commission on the Value of Death: bringing death back into life	258
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial	257
Global, regional, and national progress towards Sustainable Development Goal 3.2 for neonatal and child health: all-cause and cause-specific mortality findings from the Global Burden of Disease Study	257
Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses	256
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials	256
Depression in young people	255
Estimating global and regional disruptions to routine childhood vaccine coverage during the COVID-19 pandemic in 2020: a modelling study	255
Sputnik V COVID-19 vaccine candidate appears safe and effective	253
Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients	253
Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial	252
National, regional, and global estimates of preterm birth in 2020, with trends from 2010: a systematic analysis	252
Shanghai's life-saving efforts against the current omicron wave of the COVID-19 pandemic	251
Neuromodulation for chronic pain	248
Pandemic preparedness and COVID-19: an exploratory analysis of infection and fatality rates, and contextual factors associated with preparedness in 177 countries, from Jan 1, 2020, to Sept 30, 2021	246
Identification of vulnerable plaques and patients by intracoronary near-infrared spectroscopy and ultrasound (PROSPECT II): a prospective natural history study	245
A Lancet Commission on 70 years of women's reproductive, maternal, newborn, child, and adolescent health in China	243
Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial	240
Global, regional, and national estimates and trends in stillbirths from 2000 to 2019: a systematic assessment	240
Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial	239
Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial	238
Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial	238
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial	238
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controll	238
Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies	236
Enhancing anti-tumour efficacy with immunotherapy combinations	234
Acute respiratory distress syndrome: causes, pathophysiology, and phenotypes	233
Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, pl	233
Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial	232
Monkeypox	231
Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data	229
Vagus nerve stimulation paired with rehabilitation for upper limb motor function after ischaemic stroke (VNS-REHAB): a randomised, blinded, pivotal, device trial	228
Height and body-mass index trajectories of school-aged children and adolescents from 1985 to 2019 in 200 countries and territories: a pooled analysis of 2181 population-based studies with 65 million p	228
Responding to the opioid crisis in North America and beyond: recommendations of the Stanford–Lancet Commission	227
Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis	227
A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial	226
Wearing face masks in the community during the COVID-19 pandemic: altruism and solidarity	223
Worldwide trends in the burden of asthma symptoms in school-aged children: Global Asthma Network Phase I cross-sectional study	221
SARS-CoV-2 co-infection with influenza viruses, respiratory syncytial virus, or adenoviruses	220
The 2023 report of the Lancet Countdown on health and climate change: the imperative for a health-centred response in a world facing irreversible harms	219
The path to healthy ageing in China: a Peking University–Lancet Commission	219
Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform tria	217
Population-level risks of alcohol consumption by amount, geography, age, sex, and year: a systematic analysis for the Global Burden of Disease Study 2020	216
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial	215
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase	214
Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK	214
Mpox in people with advanced HIV infection: a global case series	212
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial	211
Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial	210
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the	209
Participation of people living with disabilities in physical activity: a global perspective	209
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)	208
Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial	208
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT):	208
A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study	207
Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden	205
Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial	204
Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-	203
Improving lung health in low-income and middle-income countries: from challenges to solutions	203
Will global health survive its decolonisation?	202
Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): a multicentre, randomised, sham-controlled trial	202
Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial	201
The Lancet Commission on ending stigma and discrimination in mental health	200
Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis	199
Contemporary medical, device, and surgical therapies for obesity in adults	198
Clinical outcomes in systematic screening for atrial fibrillation (STROKESTOP): a multicentre, parallel group, unmasked, randomised controlled trial	197
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study	196
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial	196
Influenza	194
Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials	193
Machine learning-based prediction of adverse events following an acute coronary syndrome (PRAISE): a modelling study of pooled datasets	193
Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study	192
Spontaneous subarachnoid haemorrhage	192
Thrombectomy for anterior circulation stroke beyond 6 h from time last known well (AURORA): a systematic review and individual patient data meta-analysis	191
Quantifying the effects of the COVID-19 pandemic on gender equality on health, social, and economic indicators: a comprehensive review of data from March, 2020, to September, 2021	190
Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial	190
Breastfeeding: crucially important, but increasingly challenged in a market-driven world	190
Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials	189
Defining and conceptualising the commercial determinants of health	189
Variation in the COVID-19 infection–fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis	188
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study	188
Coeliac disease	188
Estimating the cause-specific relative risks of non-optimal temperature on daily mortality: a two-part modelling approach applied to the Global Burden of Disease Study	187
Facing up to long COVID	186
The Lancet Commission on diagnostics: transforming access to diagnostics	186
Nutrition in adolescent growth and development	185
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial	185
Novel and emerging treatments for major depression	185
Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials	184
Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, ph	184